MEG in Alzheimer's Disease: unravelling the underlying network to explain the stereotypical spread of Tau protein

MEG in Alzheimer's Disease: unravelling the underlying network to explain the stereotypical spread of Tau protein - MANTA

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON48723

Enrollment

180

Registered

2018-05-23

Start date

2018-07-18

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cognitive impairment Dementia

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients: - Fulfilling the diagnostic criteria for subjective cognitive decline (SCD), mild cognitive impairment (MCI) due to AD or probable Alzheimer's disease (AD) - At least 50 years of age - Received an or a planned 18F-AV1451 PET in the context of the LUNAR, TRT AV-1451 or TITAN projects - Known amyloid status, Controls: age 20-30 years

Exclusion criteria

Exclusion criteria: Patients: - Cardiac pacemakers, ICD's and other introcorporeal devices interfering with MEG-signals - Severe claustrophobia - Specific exclusion criteria for 18F-AV1451 PET scanning or MRI scanning excluding patients from participation in the TITAN, LUNAR and TRT AV-1451 studies automatically disqualifies patients from participation in MANTA. , Controls: - Current cognitive, neurological or psychiatric disorders - Use of psychoactive medication - Contra-indications for MRI scanning - (Dental) implants, braces, cardiac pacemakers and ICD's interfering with MEG-signals - Severe claustrophobia - Current or planned pregnancy (both oral (telephone interview) and written (informed consent form) confirmation from participant).

Design outcomes

Primary

Measure	Time frame
MEG endpoints 1) Primary MEG endpoints are: - relative theta power (4-8- Hz) of the target regions - normalized directed connectivity of the target regions (lower alpha band, 8 * 10 Hz) - betweenness centrality of the target regions (lower alpha band, 8 * 10 Hz) - path length between source and target region (lower alpha band, 8 * 10 Hz) 18F-AV1451 PET scan endpoints 1) the amount of specific 18F-AV1451 binding in each of the 90 regions of the AAL-atlas	—

Measure

Time frame

MEG endpoints 1) Primary MEG endpoints are: - relative theta power (4-8- Hz) of the target regions - normalized directed connectivity of the target regions (lower alpha band, 8 * 10 Hz) - betweenness centrality of the target regions (lower alpha band, 8 * 10 Hz) - path length between source and target region (lower alpha band, 8 * 10 Hz) 18F-AV1451 PET scan endpoints 1) the amount of specific 18F-AV1451 binding in each of the 90 regions of the AAL-atlas

—

Secondary

Measure	Time frame
MEG endpoints 2) Secondary MEG endpoints are: 2.1) all other frequency specific MEG endpoints 2.2) modularity analyses 2.3) multiplex network analyses	—

Countries

Netherlands

Outcome results